Repligen (Repligen) Operating Cash Flow per Share : $2.01 (TTM As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Repligen Operating Cash Flow per Share?

Repligen's operating cash flow per share for the three months ended in Dec. 2023 was $0.52. Repligen's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.01.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Repligen was -32.50% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 20.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 26.00% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 20.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Repligen's Operating Cash Flow per Share or its related term are showing as below:

RGEN' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -60.6 Med: 17.2 Max: 143.4
Current: 20.3

During the past 13 years, Repligen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 143.40% per year. The lowest was -60.60% per year. And the median was 17.20% per year.

RGEN's 3-Year OCF Growth Rate is ranked better than
73.52% of 691 companies
in the Medical Devices & Instruments industry
Industry Median: 2.9 vs RGEN: 20.30

Repligen Operating Cash Flow per Share Historical Data

The historical data trend for Repligen's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Operating Cash Flow per Share Chart

Repligen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

1.37

1.16

2.08

3.00

2.02

Repligen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															1.09	0.20	0.61	0.69	0.52

Competitive Comparison of Repligen's Operating Cash Flow per Share

For the Medical Instruments & Supplies subindustry, Repligen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repligen's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Repligen's Price-to-Operating-Cash-Flow falls into.

Repligen Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Repligen's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	113.918	/	56.377
	=	2.02

Repligen's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	29.065	/	55.816
	=	0.52

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.01

Repligen Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Repligen's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Repligen (Repligen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

RGN:Germany RGN:Germany

Address

41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453

Website

https://www.repligen.com

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Executives

Christine Gebski	officer: See Remarks	C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot	officer: President and CCO	C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland	officer: CFO	10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes	director	579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres	officer: CFO	REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt	director, officer: Chief Executive Officer	41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel	officer: Senior VP, R&D	41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund	officer: SVP, Global Operations & IT	C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov	director	C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr	director
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox	director	C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre	director	C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453